EC study reveals differences between pancreatic cancer tumors in black patients

NEWYou can now listen to Fox News articles!

A University of Cincinnati study found differences in pancreatic tumors that could explain why this type of cancer affects some patients differently, potentially leading to more personalized treatments.

Researchers examined 22 pancreatic tumors from patients of different racial backgrounds across the United States, looking for differences in cancer cells and how the immune system responds to them. The study included seven black patients and 15 non-African American patients.

The results were published in the journal Cancer Research.

FDA APPROVES DAILY PILL FOR DEADLY CANCER AFTER PATIENT SURVIVAL RATES NEARLY DOUBLED

The black patients’ tumors contained fewer pancreatic cancer cells of the most common type and more cells with a mix of different characteristics, the researchers found.

Some of these cellular characteristics have been associated with drug resistance, but the study did not establish whether they affected patients’ treatment outcomes.

Man receiving immunotherapy

A University of Cincinnati study found differences in pancreatic tumors that could explain why this type of cancer affects some patients differently. (iStock)

Additionally, the black patients’ tumors contained more B cells, a type of immune cell, and larger clusters of immune cells. Researchers have found evidence that some B cells may inhibit the body’s response to cancer, although the significance of these differences is unclear.

PATIENTS REMAIN CANCER-FREE NEARLY 3 YEARS AFTER RECEIVING EXPERIMENTAL IMMUNOTHERAPY

Dr. Raymond Wadlow, a gastrointestinal medical oncologist at the Inova Schar Cancer Institute in Virginia, said using immunotherapy to help the immune system attack disease has proven particularly challenging in pancreatic cancer.

“This has been very difficult to do in pancreatic cancer because the pancreatic tumor subverts the immune system so that it fights for itself rather than for the host or the rest of the body,” Wadlow, who was not involved in the study, told Fox News Digital.

Chemo patient with doctor

The black patients’ tumors contained more B cells, a type of immune cell, and larger clusters of immune cells. Researchers have found signs that certain B cells may inhibit the body’s response to cancer. (iStock)

The study found no significant differences between the groups in major genetic changes known to cause the disease.

Pancreatic cancer is about 20% more likely to develop in Black Americans than in non-African Americans, researchers say.

WHERE YOU LIVE COULD SHAPE YOUR RISK OF CANCER MORTALITY, STUDY SUGGESTS

The findings highlight the importance of including patients from different backgrounds in cancer research, according to the study’s lead author, Nina Steele, Ph.D., assistant professor at the UC School of Medicine.

“This study shows that ignoring ancestry diversity in medical research leaves blind spots in the search for a cure,” she told Fox News Digital.

A man takes a genetic test

An oncologist (not pictured) encouraged newly diagnosed patients to learn about hereditary genetic testing, which can identify inherited mutations that may also affect loved ones. (iStock)

Wadlow noted that pancreatic cancers can share major DNA mutations, but can differ significantly in how their cells behave and interact with neighboring immune cells and surrounding tissues.

“These differences may also vary across patient populations, for example between black and non-black patients,” he told Fox News Digital.

“While intriguing, these results are still far from changing patient care.”

“This is potentially important both for understanding disparities in pancreatic cancer and, ultimately, for developing more individualized treatments.”

Pancreatic cancer can vary from tumor to tumor, and even within the same tumor, Wadlow explained. “The cancer cell itself is only part of the story,” he said.

3D rendering of pancreatic cancer

Pancreatic cancer is about 20% more likely to develop in Black Americans than in non-African Americans, researchers say. (iStock)

Surrounding immune cells and tissues can affect a tumor’s behavior and response to treatment, helping to explain why a single treatment approach may not work for all patients.

The results have several limitations.

CLICK HERE FOR MORE HEALTH STORIES

Researchers have not established how intermediate tumor cells affect survival or whether they respond differently to standard chemotherapy, Steele said.

The team also needs to study pancreatic tissue from people without cancer to better understand when these differences develop.

CLICK HERE TO SUBSCRIBE TO OUR HEALTH NEWSLETTER

Wadlow cautioned that race and genetic ancestry do not fully account for environmental, socioeconomic and biological factors that could explain the findings.

Larger studies involving patients from diverse backgrounds are needed to determine whether these differences affect treatment outcomes or survival, the oncologist said.

Man receiving immunotherapy

Immunotherapy to help the immune system attack cancer has proven particularly difficult in pancreatic cancer, an oncologist said. (Aaron Chown/PA Images via Getty Images)

“Although intriguing, these results are still far from changing patient care,” he added.

Wadlow encouraged newly diagnosed patients to ask about hereditary genetic testing, which can identify inherited mutations that may also affect loved ones.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“If we find a hereditary mutation, then family members can be tested,” he said.

Steele said the findings also highlight the need to conduct clinical trials representing patients affected by pancreatic cancer.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“It’s also a reminder to the medical system to ensure that clinical trials reflect the entire at-risk population, to find treatments that can help all patients, not just some patients,” she told Fox News Digital.

The research was funded in part by the National Cancer Institute.

Gn Health

Logo